切换导航
  • 比较产品
我的购物车

ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Human T cell activation and expansion reagent
率先评论此产品
添加并比较

产品号 #10970_C

Human T cell activation and expansion reagent

产品优势


  • Robust activation and expansion of human T cells without the use of magnetic beads, feeder cells, or antigen

  • Provides a gentle activation stimulus that maintains high viability of activated and expanded T cells

  • Highly stable, filter-sterilized soluble reagent

main product photo
ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator
概述
实验数据
产品说明书及文档
应用领域
相关材料与文献

概述

Achieve robust activation and expansion of T cells in the absence of magnetic beads, feeder cells, or antigens.

This product’s gentle activation stimulus ensures a high viability of activated T cells, which can be further expanded in ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981) or other media for culturing human T cells. ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator consists of soluble antibody complexes that bind to and cross-link CD3, CD28, and CD2 cell surface ligands, thereby providing the required primary and co-stimulatory signals for T cell activation.

This product is designed for research applications. If you require reagents suitable for use in cell therapy manufacturing, ImmunoCult™ Human CD3/CD28/CD2 T Cell Activators (Catalog #100-0785) are produced under relevant GMPs.

Contains
• Anti-human CD3 monospecific antibody complex <br> • Anti-human CD28 monospecific antibody complex <br> • Anti-human CD2 monospecific antibody complex
 
Subtype
Supplements
 
Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
 
Species
Human
 
Application
Activation, Cell Culture, Expansion
 
Brand
ImmunoCult
 
Area of Interest
Immunology, Cell Therapy Development
 

Data Figures

Activated Morphology of Human T Cells Stimulated With ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Figure 1. Activated Morphology of Human T Cells Stimulated With ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Image of human T cells isolated using the EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator, and cultured in ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981).

Activation of EasySep™ Isolated Human T Cells Stimulated With ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Figure 2. Activation of EasySep™ Isolated Human T Cells Stimulated With ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

EasySep™-isolated human T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator and cultured in ImmunoCult™-XF T Cell Expansion Medium. Activation of viable CD3+ T cells was assessed by CD25 expression using flow cytometry. On day 0, the frequency of CD25 positive cells was (A) 5.6 ± 2.4% (mean ± SD). Following 3 days of culture, the frequency of CD25 positive cells was (B) 88.8 ± 3.2% (mean ± SD) when stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator.

Robust Human T Cell Expansion with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Figure 3. Robust Human T Cell Expansion with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

EasySep™-isolated human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF T Cell Expansion Medium supplemented with Human Recombinant IL-2. On day 0, 1 x 10^6 EasySep™-isolated human T cells were stimulated with 25 μL of ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF T Cell Expansion Medium supplemented with 10 ng/mL Human Recombinant IL-2. On days 3, 5, 7, and 10, viable cells were counted and fresh medium supplemented with IL-2 was added. No additional ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator was added during the 12-day culture period (mean ± SD in 6 experiments with 3 donors).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator
Catalog #
10990, 10970
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator
Catalog #
10990, 10970
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (22)

T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Isolate Human Immune Cells
Brochure
Isolate Human Immune Cells
Optimization of Human T Cell Expansion Protocol: Effects of Early Cell Dilution
Technical Bulletin
Optimization of Human T Cell Expansion Protocol: Effects of Early Cell Dilution
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Antigen Processing and Presentation
Wallchart
Antigen Processing and Presentation
The Immune Response to HIV Poster
Wallchart
The Immune Response to HIV Poster
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
How to Isolate Cells Directly from Whole Blood Using the EasySep™ Purple/Silver Magnets
4:30
Video
How to Isolate Cells Directly from Whole Blood Using the EasySep™ Purple/Silver Magnets
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
0:59
Video
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...
Accelerating T Cell Therapy Research
Webinar
Accelerating T Cell Therapy Research
Qualification of Ancillary/Raw Materials for Clinical Use
54:39
Webinar
Qualification of Ancillary/Raw Materials for Clinical Use
Next-Generation Tools to Advance Your Human T Cell Research
32:50
Webinar
Next-Generation Tools to Advance Your Human T Cell Research
Online Immunology Journal Club: Human In Vitro T Cell Development
31:22
Webinar
Online Immunology Journal Club: Human In Vitro T Cell Development
T Cell Differentiation and Cancer Immunity
48:32
Webinar
T Cell Differentiation and Cancer Immunity
Optimization of Human T Cell Activation and Expansion Protocols Improves Efficiency of Genetic Modification and Overall Cell Yield
Scientific Poster
Optimization of Human T Cell Activation and Expansion Protocols Improves Efficiency of Genetic Modif...
Workflow Solutions for Human T Cell Isolation and Expansion
Scientific Poster
Workflow Solutions for Human T Cell Isolation and Expansion
Rapid Expansion of Functional Human T Cells Using a Novel Serum-Free and Xeno-Free Culture Medium
Scientific Poster
Rapid Expansion of Functional Human T Cells Using a Novel Serum-Free and Xeno-Free Culture Medium
Human T Cell Expansion Course
On-Demand Training
Human T Cell Expansion Course

Publications (5)

Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. M. Asare-Werehene et al. Cancer research 2020 sep

Abstract

Although initial treatment of ovarian cancer is successful, tumors typically relapse and become resistant to treatment. Because of poor infiltration of effector T cells, patients are mostly unresponsive to immunotherapy. Plasma gelsolin (pGSN) is transported by exosomes (small extracellular vesicle, sEV) and plays a key role in ovarian cancer chemoresistance, yet little is known about its role in immunosurveillance. Here, we report the immunomodulatory roles of sEV-pGSN in ovarian cancer chemoresistance. In chemosensitive conditions, secretion of sEV-pGSN was low, allowing for optimal CD8+ T-cell function. This resulted in increased T-cell secretion of IFN$\gamma$, which reduced intracellular glutathione (GSH) production and sensitized chemosensitive cells to cis-diaminedichloroplatinum (CDDP)-induced apoptosis. In chemoresistant conditions, increased secretion of sEV-pGSN by ovarian cancer cells induced apoptosis in CD8+ T cells. IFN$\gamma$ secretion was therefore reduced, resulting in high GSH production and resistance to CDDP-induced death in ovarian cancer cells. These findings support our hypothesis that sEV-pGSN attenuates immunosurveillance and regulates GSH biosynthesis, a phenomenon that contributes to chemoresistance in ovarian cancer. SIGNIFICANCE: These findings provide new insight into pGSN-mediated immune cell dysfunction in ovarian cancer chemoresistance and demonstrate how this dysfunction can be exploited to enhance immunotherapy.
View publication
Competition between PAF1 and MLL1/COMPASS confers the opposing function of LEDGF/p75 in HIV latency and proviral reactivation. R. Gao et al. Science advances 2020 may

Abstract

Transcriptional status determines the HIV replicative state in infected patients. However, the transcriptional mechanisms for proviral replication control remain unclear. In this study, we show that, apart from its function in HIV integration, LEDGF/p75 differentially regulates HIV transcription in latency and proviral reactivation. During latency, LEDGF/p75 suppresses proviral transcription via promoter-proximal pausing of RNA polymerase II (Pol II) by recruiting PAF1 complex to the provirus. Following latency reversal, MLL1 complex competitively displaces PAF1 from the provirus through casein kinase II (CKII)-dependent association with LEDGF/p75. Depleting or pharmacologically inhibiting CKII prevents PAF1 dissociation and abrogates the recruitment of both MLL1 and Super Elongation Complex (SEC) to the provirus, thereby impairing transcriptional reactivation for latency reversal. These findings, therefore, provide a mechanistic understanding of how LEDGF/p75 coordinates its distinct regulatory functions at different stages of the post-integrated HIV life cycles. Targeting these mechanisms may have a therapeutic potential to eradicate HIV infection.
View publication
PD-1+ melanocortin receptor dependent-Treg cells prevent autoimmune disease. F. Muhammad et al. Scientific reports 2019 nov

Abstract

Experimental autoimmune uveoretinitis (EAU) is a mouse model of human autoimmune uveitis marked by ocular autoantigen-specific regulatory immunity in the spleen. The melanocortin 5 receptor (MC5r) and adenosine 2 A receptor (A2Ar) are required for induction of post-EAU regulatory T cells (Tregs) which provide resistance to EAU. We show that blocking the PD-1/PD-L1 pathway prevented suppression of EAU by post-EAU Tregs. A2Ar induction of PD-1+FoxP3+ Tregs in uveitis patients was similar compared to healthy controls, but was significantly reduced with melanocortin stimulation. Further, lower body mass index correlated with responsiveness to stimulation of this pathway. These observations indicate an importance of the PD-1/PD-L1 pathway to provide resistance to relapsing uveitis and shows a reduced capacity of uveitis patients to induce Tregs when stimulated through melanocortin receptors, but that it is possible to bypass this part of the pathway through direct stimulation of A2Ar.
View publication
View All Publications
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。